Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma
Clinical trial NCT02263508 · TERMINATED
Trial details
- NCT number
- NCT02263508
- Sponsor
- Amgen
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-12-08
- Primary completion
- 2021-03-11
- Enrollment
- 713
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.